

RESTRICTED BENEFIT CRITERIA - SEREVENT®

PROVINCE/PROGRAM	INDICATION	CRITERIA
British Columbia SA	ASTHMA	Asthma uncontrolled on ICS
	COPD	COPD that cannot receive a LAMA
New Brunswick SA	ASTHMA	Asthma uncontrolled on ICS
	COPD	Moderate to severe symptomatic COPD Exacerbating COPD
Non-insured health benefits LU	ASTHMA	Asthma symptomatic on ICS
	COPD	COPD uncontrolled on SAMA, SABA or tiotropium
Newfoundland and Labrador SA	ASTHMA	Asthma symptomatic on ICS
	COPD	Moderate to severe symptomatic COPD Exacerbating COPD
Nova Scotia EDS	ASTHMA	Asthma symptomatic on ICS
	COPD	Moderate to severe symptomatic COPD Exacerbating COPD
Ontario LU Code	ASTHMA	132 Asthma symptomatic on ICS
	COPD	391 Moderate to severe COPD symptomstic on LAMA + SABA
Prince Edward Island SA	ASTHMA	Asthma not otherwise specified. To be used with ICS.
	COPD	Moderate to severe symptomatic COPD Exacerbating COPD
Saskatchewan EDS	ASTHMA	Asthma uncontrolled on ICS
	COPD	COPD not otherwise specified
Yukon EDS	ASTHMA	Asthma uncontrolled on ICS
	COPD	Moderate to severe COPD that cannot receive a LAMA

COPD: chronic obstructive pulmonary disease, EDS: Exception Drug Status, ICS: inhaled corticosteroids, LABA: long-acting beta-agonist, LAMA: long-acting muscarinic antagonist, LU: limited use, SA: Special Authorization, SABA: short-acting beta-agonist